Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting
dc.contributor.author | O’leary, Michael P. | en_US |
dc.contributor.author | Wei, John T. | en_US |
dc.contributor.author | Roehrborn, Claus G. | en_US |
dc.contributor.author | Miner, Martin | en_US |
dc.date.accessioned | 2010-06-01T19:47:55Z | |
dc.date.available | 2010-06-01T19:47:55Z | |
dc.date.issued | 2008-06 | en_US |
dc.identifier.citation | O’Leary, Michael P.; Wei, John T.; Roehrborn, Claus G.; Miner, Martin (2008). "Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting." BJU International 101(12): 1531-1535. <http://hdl.handle.net/2027.42/72931> | en_US |
dc.identifier.issn | 1464-4096 | en_US |
dc.identifier.issn | 1464-410X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/72931 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18445080&dopt=citation | en_US |
dc.description.abstract | To evaluate the association between the International Prostate Symptom Score (IPSS) bother question (BQ) and a validated disease-specific quality-of-life questionnaire, the Benign Prostatic Hyperplasia (BPH) Impact Index (BPH-II), using the BPH Registry and Patient Survey database. PATIENTS AND METHODS The BPH Registry and Patient Survey is a multicentre, longitudinal, observational database of management practices and patient outcomes in a population of patients with BPH in the USA, managed with watchful waiting or pharmacotherapy. Men enrolled in the BPH Registry who completed the IPSS BQ and the four-item BPH-II at enrolment were identified. The association between the IPSS BQ score and the BPH Impact Index was assessed using Spearman rank correlation. RESULTS At baseline (enrolment visit), 6439 men (mean age 66 years) completed the IPSS BQ and the BPH-II. The mean (sd) score of the IPSS BQ was 2.5 (1.4) and of the BPH-II was 2.8 (2.8). Based on responses to the BPH-II, at least half the men reported that their urinary symptoms were associated with physical discomfort, worry about their health, and bothersomeness. The IPSS BQ score was significantly correlated ( P < 0.001) with the BPH-II ( r = 0.68) and each of its four questions (physical discomfort, r = 0.52; worry about health, r = 0.53; bothersomeness of trouble with urination, r = 0.67; and time kept from usual activities, r = 0.44). CONCLUSIONS The IPSS BQ score has a strong and positive correlation with the BPH-II among men enrolled in the BPH Registry. The IPSS BQ is a convenient tool for assessing disease-specific quality of life when determining treatment strategies and evaluating treatment outcomes in men with BPH. | en_US |
dc.format.extent | 134120 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | © 2008 BJU International | en_US |
dc.subject.other | Benign Prostatic Hyperplasia | en_US |
dc.subject.other | Lower Urinary Tract Symptoms | en_US |
dc.subject.other | Bother Score | en_US |
dc.subject.other | Disease-specific Quality of Life | en_US |
dc.title | Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | * The University of Michigan, Ann Arbor, MI, | en_US |
dc.contributor.affiliationother | † The University of Texas Southwestern Medical Center, Dallas, TX, and | en_US |
dc.contributor.affiliationother | † Warren Alpert School of Medicine of Brown University, Providence, RI, USA | en_US |
dc.identifier.pmid | 18445080 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/72931/1/j.1464-410X.2008.07574.x.pdf | |
dc.identifier.doi | 10.1111/j.1464-410X.2008.07574.x | en_US |
dc.identifier.source | BJU International | en_US |
dc.identifier.citedreference | Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474 – 9 | en_US |
dc.identifier.citedreference | Girman CJ, Epstein RS, Jacobsen SJ et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 825 – 31 | en_US |
dc.identifier.citedreference | O’Leary MP. LUTS, ED and QOL: alphabet soup or real concerns to aging men? Urology 2000; 56: 7 – 11 | en_US |
dc.identifier.citedreference | 4 AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530 – 47 | en_US |
dc.identifier.citedreference | Barry MJ, Fowler FJ Jr, O’Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549 – 57 | en_US |
dc.identifier.citedreference | Cockett ATK, Khoury S, Aso Y et al. eds. The 2nd International Consultation on BPH, Proceedings. Jersey, Channel Islands: Scientific Communication International, Ltd, 1993 | en_US |
dc.identifier.citedreference | Batista-Miranda JE, Diez MD, Bertran PA, Villavicencio H. Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions. Pharmacoeconomics 2001; 19: 1079 – 90 | en_US |
dc.identifier.citedreference | Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association. Medical Care 1995; 33: AS145 – 55 | en_US |
dc.identifier.citedreference | Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637 – 49 | en_US |
dc.identifier.citedreference | Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160: 12 – 6 | en_US |
dc.identifier.citedreference | Yoshimura K, Arai Y, Ichioka K, Terada N, Matsuta Y, Okubo K. Symptom-specific quality of life in patients with benign prostatic hyperplasia. Int J Urol 2002; 9: 485 – 90 | en_US |
dc.identifier.citedreference | Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92: 257 – 61 | en_US |
dc.identifier.citedreference | Ganpule AP, Desai MR, Desai MM, Wani KD, Bapat SD. Natural history of lower urinary tract symptoms: preliminary report from a community-based Indian study. BJU Int 2004; 94: 332 – 4 | en_US |
dc.identifier.citedreference | Andersson SO, Rashidkhani B, Karlberg L, Wolk A, Johansson JE. Prevalence of lower urinary tract symptoms in men aged 45–79 years: a population-based study of 40 0 00 Swedish men. BJU Int 2004; 94: 327 – 31 | en_US |
dc.identifier.citedreference | O’Leary MP. Validity of the ‘bother score’ in the evaluation and treatment of symptomatic benign prostatic hyperplasia. Rev Urol 2005; 7: 1 – 10 | en_US |
dc.identifier.citedreference | Roehrborn CG, Nuckolls JG, Wei JT, Steers W. The BPH Registry and Patient Survey: study design, methods, and patient baseline characteristics. BJU Int 2007; 100: 813 – 9 | en_US |
dc.identifier.citedreference | Boyle P, Robertson C, Mazzetta C et al. The relationship between lower urinary tract symptoms and health status: the UREPIK study. BJU Int 2003; 92: 575 – 80 | en_US |
dc.identifier.citedreference | O’Leary M, Litwin M, Manyak M, Miner M, Penson D, Roehrborn C. Correlation of International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index and SF-12 in a practice setting. J Urol 2005; 173 ( 4 Suppl. ): Abstract 4 | en_US |
dc.identifier.citedreference | Rhodes PR, Krogh RH, Bruskewitz RC. Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urology 1999; 53: 1090 – 8 | en_US |
dc.identifier.citedreference | Donovan JL, Kay HE, Peters TJ et al. Using the ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-‘BPH’ Study. International Continence Society – Benign Prostatic Hyperplasia. Br J Urol 1997; 80: 712 – 21 | en_US |
dc.identifier.citedreference | Berges RR, Pientka L, Hofner K, Senge T, Jonas U. Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol 2001; 39: 682 – 7 | en_US |
dc.identifier.citedreference | Jacobsen SJ, Girman CJ, Guess HA et al. Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms. Urology 1993 2003; 42: 663 – 71 | en_US |
dc.identifier.citedreference | 23 AUA Practice Guidelines Committee. AUA Guideline on Management of Benign Prostatic Hyperplasia. Chapter 3: results of the treatment outcomes analyses. American Urological Association. Available at: http://www.AUAnet.org. Accessed 27 October 2007 | en_US |
dc.identifier.citedreference | Sagnier PP, MacFarlane G, Teillac P, Botto H, Richard F, Boyle P. Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J Urol 1995; 153: 669 – 73 | en_US |
dc.identifier.citedreference | Stroberg P, Boman H, Gellerstedt M, Hedelin H. Relationships between lower urinary tract symptoms, the bother they induce and erectile dysfunction. Scand J Urol Nephrol 2006; 40: 307 – 12 | en_US |
dc.identifier.citedreference | Ushijima S, Ukimura O, Okihara K, Mizutani Y, Kawauchi A, Miki T. Visual analog scale questionnaire to assess quality of life specific to each symptom of the International Prostate Symptom Score. J Urol 2006; 176: 665 – 71 | en_US |
dc.identifier.citedreference | Sarma AV, Wei JT, Jacobson DJ et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men’s Health Study. Urology 2003; 61: 1086 – 91 | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.